Clinical Trial

Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)

Study acronym: MEASURE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and inadequately controlled Type 2 Diabetes (T2D) despite guideline-directed therapy, including Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)-based agents.
Trial Details
NCT Number NCT07639684
Lead Sponsor Boston Scientific Corporation
Conditions Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Enrollment 50 participants
Start Date 2027-02
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-10